LightOx have developed a range of fluorescent probes which are now commercially available via Merck Millipore and are currently developing a LightBox for use in the research field. We are happy to share a list of these probes if this is of interest.
LightOx’s core aim is to develop new light activated therapeutic solutions to improve the functional and long-term outcomes for patients with oral cancer. Worldwide, oral cancer are the 6th most prevalent with some of the worst global 5 year survival rates; 2 of every 5 people will die within 5 years. We are developing new solutions to provide early detection and non-surgical eradication of these cancers.
We have now identified our lead candidate for use in tongue cancer. This is currently going through toxicity and safety testing with the aim to have first in man towards the end of 2021.
